Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
J Am Coll Cardiol. 2022 Aug 16;80(7):697-718. doi: 10.1016/j.jacc.2022.05.038.
PVDOMICS (Pulmonary Vascular Disease Phenomics) is a precision medicine initiative to characterize pulmonary vascular disease (PVD) using deep phenotyping. PVDOMICS tests the hypothesis that integration of clinical metrics with omic measures will enhance understanding of PVD and facilitate an updated PVD classification.
The purpose of this study was to describe clinical characteristics and transplant-free survival in the PVDOMICS cohort.
Subjects with World Symposium Pulmonary Hypertension (WSPH) group 1-5 PH, disease comparators with similar underlying diseases and mild or no PH and healthy control subjects enrolled in a cross-sectional study. PH groups, comparators were compared using standard statistical tests including log-rank tests for comparing time to transplant or death.
A total of 1,193 subjects were included. Multiple WSPH groups were identified in 38.9% of PH subjects. Nocturnal desaturation was more frequently observed in groups 1, 3, and 4 PH vs comparators. A total of 50.2% of group 1 PH subjects had ground glass opacities on chest computed tomography. Diffusing capacity for carbon monoxide was significantly lower in groups 1-3 PH than their respective comparators. Right atrial volume index was higher in WSPH groups 1-4 than comparators. A total of 110 participants had a mean pulmonary artery pressure of 21-24 mm Hg. Transplant-free survival was poorest in group 3 PH.
PVDOMICS enrolled subjects across the spectrum of PVD, including mild and mixed etiology PH. Novel findings include low diffusing capacity for carbon monoxide and enlarged right atrial volume index as shared features of groups 1-3 and 1-4 PH, respectively; unexpected, frequent presence of ground glass opacities on computed tomography; and sleep alterations in group 1 PH, and poorest survival in group 3 PH. PVDOMICS will facilitate a new understanding of PVD and refine the current PVD classification. (Pulmonary Vascular Disease Phenomics Program PVDOMICS [PVDOMICS]; NCT02980887).
PVDOMICS(肺血管疾病表型组学)是一项精准医学计划,旨在通过深度表型分析来描述肺血管疾病(PVD)。PVDOMICS 检验了这样一种假设,即整合临床指标与组学测量结果将增强对 PVD 的理解,并促进更新的 PVD 分类。
本研究旨在描述 PVDOMICS 队列的临床特征和无移植生存率。
在这项横断面研究中,纳入了患有世界肺高压研讨会(WSPH)第 1-5 组肺动脉高压(PH)、具有相似基础疾病且 PH 程度较轻或无 PH 以及健康对照的受试者。使用标准统计检验(包括比较移植或死亡时间的对数秩检验)比较 PH 组、对照组。
共纳入 1193 名受试者。38.9%的 PH 受试者被分为多个 WSPH 组。与对照组相比,1 组、3 组和 4 组 PH 受试者夜间更易出现低氧血症。1 组 PH 受试者中,50.2%的人胸部 CT 有磨玻璃影。1-3 组 PH 受试者的一氧化碳弥散量明显低于各自的对照组。与对照组相比,WSPH 第 1-4 组的右心房容积指数更高。共有 110 名参与者的平均肺动脉压为 21-24mmHg。3 组 PH 的无移植生存率最差。
PVDOMICS 纳入了 PVD 谱中的受试者,包括轻度和混合病因 PH。新发现包括:1-3 组和 1-4 组 PH 分别有共同的特征,即一氧化碳弥散量低和右心房容积指数增大;CT 上意外且频繁出现磨玻璃影;1 组 PH 有睡眠改变;3 组 PH 的生存率最差。PVDOMICS 将促进对 PVD 的新认识,并完善目前的 PVD 分类。(肺血管疾病表型组学计划 PVDOMICS [PVDOMICS];NCT02980887)